Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

‘Tell Me Lies’ Creator Dives Into That Jaw-Dropping Finale and Explains Why the Show Is Ending: “We Couldn’t F*** It Up” Meaghan Oppenheimer unravels the chaotic season three and series finale that ...

After eight episodes of post-apocalypse insanity and plenty of irradiated creatures, Fallout wrapped up Season 2 with the season finale, “The Strip,” this week. Given that multiple characters are left ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Learn how to implement the Adadelta optimization algorithm from scratch in Python. This tutorial explains the math behind Adadelta, why it was introduced as an improvement over Adagrad, and guides you ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...